Androgen Deprivation Therapy Use Increases the Risk of Heart Failure in Patients With Prostate Cancer: A Population‐Based Cohort Study

Kao, Hui-Han; Li, I‐Hsun; Pan, Ke-Ting; Shih, Jui‐Hu; Chou, Yu‐Ching; Wu, Sheng‐Tang

doi:10.1002/jcph.1332

Cited by 12 publications

(9 citation statements)

References 34 publications

(91 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main mediators of these effects are p53, heat shock protein HSP27, quinone reductases as well as nitric oxide [102]. Considering that several cancer therapies like androgen deprivation therapy are conceived to indirectly contribute to the development of hyperglycemia, dyslipidemia and metabolic syndrome, which are well-established causal risk factors of atherosclerosis [103,104], the use of resveratrol in this category of patients could be a therapeutic window of interest in the cardio-oncological field.…”

Section: Resveratrol In Cardio-oncologymentioning

confidence: 99%

Resveratrol in Cancer Patients: From Bench to Bedside

Berretta

Bignucolo

Francia

et al. 2020

IJMS

View full text Add to dashboard Cite

Resveratrol (3,5, is a natural phytoalexin that accumulates in several vegetables and fruits like nuts, grapes, apples, red fruits, black olives, capers, red rice as well as red wines. Being both an extremely reactive molecule and capable to interact with cytoplasmic and nuclear proteins in human cells, resveratrol has been studied over the years as complementary and alternative medicine (CAM) for the therapy of cancer, metabolic and cardiovascular diseases like myocardial ischemia, myocarditis, cardiac hypertrophy and heart failure. This review will describe the main biological targets, cardiovascular outcomes, physico-chemical and pharmacokinetic properties of resveratrol in preclinical and clinical models implementing its potential use in cancer patients.properties of resveratrol are, however, marked by a pharmacokinetic profile and by an unfavorable oral bioavailability, which requires a thorough analysis. To date, to the best of our knowledge, scientific papers and reviews summarizing multiple characteristics of resveratrol, its pharmacokinetic, pharmacodynamic profiles and potential drug interaction in oncology are lacking in literature. Therefore, this review aimed to describe the potential use of resveratrol in cancer management presenting the main biochemical pathways involved, issues and potential uses in cancer patients. Moreover, the involvement of resveratrol in cardioncology, its potential use for risk reduction of myocardial ischemia, myocarditis, cardiac hypertrophy as well as heart failure are also discussed. To endorse this review, we made a comprehensive search on PubMed, Web of Science and SciFinder. The search terms were "resveratrol" combined with "cardioncology" or "cancer" or "drug-food" or "cardiology" or "pharmacokinetic" or "pharmacodynamic". Physico-Chemical and Pharmacokinetic Properties of ResveratrolResveratrol is a low molecular weight phyto-polyphenol of 228 Da that appears as an off-white powder with lipophilic properties (octanol/water partition coefficient, log Kow = 3.1). Its melting point is between 253 and 255 • C, and its solubility in water is very low (3 mg/100 mL) [8]. The ethylene bridge due to a limited degree of freedom generates two geometric isomers: cis-resveratrol and trans-resveratrol ( Figure 1) [5]. These isoforms co-exist in resveratrol extracts even if a greater biological activity and stability are attributed to trans-resveratrol. Comparing to the geometric isomers, the nearly planar structure of trans-resveratrol is less flexible than the non-planar structure of cis-resveratrol, but it possesses a lower repulsive energy that ensures it, albeit small, higher stability. Isomerization of trans-resveratrol to cis-resveratrol occurs via molecule breakdown when trans-resveratrol is exposed to UV radiation at a wavelength of 254 or 366 nm, to high pH conditions or in plants during fermentation processes [5,9]. In analyzing some physical-chemical aspects of resveratrol, Zupancic et al. showed how trans-resveratrol is rapidly degradable in high-pH solutions. In par...

show abstract

Section: Resveratrol In Cardio-oncologymentioning

confidence: 99%

Resveratrol in Cancer Patients: From Bench to Bedside

Berretta

Bignucolo

Francia

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Emerging reports have indicated the wide-ranging impact of PCa treatment strategies like ADT on patients’ risk of developing CVDs, like hypertension, CAD, arrhythmia and cardiac arrests [ 8 , 9 , 10 , 11 , 12 , 13 , 14 ]. Though the interconnection between cardiovascular health and PCa has been reported, the molecular mechanisms underlying this interconnection have not been completely explored.…”

Section: Discussionmentioning

confidence: 99%

“…Androgen deprivation therapy (ADT) remains the cornerstone of treatment for metastatic PCa [ 4 , 5 , 6 , 7 ], but most patients experience disease relapse due to therapeutic failure. Several studies in recent times have suggested a strong connection between cardiovascular diseases (CVDs) and PCa [ 8 , 9 , 10 , 11 , 12 , 13 , 14 ]. ADT reportedly elevates the risk for heart failure and other CVDs like hypertension and stroke in men without pre-existing cardiovascular conditions, which is even more in patients with pre-existing CVDs [ 8 , 9 , 10 , 11 , 12 , 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

“…Several studies in recent times have suggested a strong connection between cardiovascular diseases (CVDs) and PCa [ 8 , 9 , 10 , 11 , 12 , 13 , 14 ]. ADT reportedly elevates the risk for heart failure and other CVDs like hypertension and stroke in men without pre-existing cardiovascular conditions, which is even more in patients with pre-existing CVDs [ 8 , 9 , 10 , 11 , 12 , 13 , 14 ]. Indeed, cardiovascular complications are the most common cause of death in PCa patients [ 15 , 16 , 17 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cardiovascular Complications in Patients with Prostate Cancer: Potential Molecular Connections

Kakkat

Pramanik

Singh

et al. 2023

IJMS

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) and complications are often seen in patients with prostate cancer (PCa) and affect their clinical management. Despite acceptable safety profiles and patient compliance, androgen deprivation therapy (ADT), the mainstay of PCa treatment and chemotherapy, has increased cardiovascular risks and metabolic syndromes in patients. A growing body of evidence also suggests that patients with pre-existing cardiovascular conditions show an increased incidence of PCa and present with fatal forms of the disease. Therefore, it is possible that a molecular link exists between the two diseases, which has not yet been unraveled. This article provides insight into the connection between PCa and CVDs. In this context, we present our findings linking PCa progression with patients’ cardiovascular health by performing a comprehensive gene expression study, gene set enrichment (GSEA) and biological pathway analysis using publicly available data extracted from patients with advanced metastatic PCa. We also discuss the common androgen deprivation strategies and CVDs most frequently reported in PCa patients and present evidence from various clinical trials that suggest that therapy induces CVD in PCa patients.

show abstract

“…Successively, fine results have been reported in NHIRD-related literature relating to breast cancer [17, 18] and hepatoma [19]. Prostate cancer–related issues with NHIRD have also been published [20, 21, 22]. However, these studies related to prostate cancer have not focused on cancerous recurrence or death.…”

Section: Introductionmentioning

confidence: 99%

Prediction of recurrence-associated death from localized prostate cancer with a charlson comorbidity index–reinforced machine learning model

et al. 2019

View full text Add to dashboard Cite

AbstractResearch has failed to resolve the dilemma experienced by localized prostate cancer patients who must choose between radical prostatectomy (RP) and external beam radiotherapy (RT). Because the Charlson Comorbidity Index (CCI) is a measurable factor that affects survival events, this research seeks to validate the potential of the CCI to improve the accuracy of various prediction models. Thus, we employed the Cox proportional hazard model and machine learning methods, including random forest (RF) and support vector machine (SVM), to model the data of medical records in the National Health Insurance Research Database (NHIRD). In total, 8581 individuals were enrolled, of whom 4879 had received RP and 3702 had received RT. Patients in the RT group were older and exhibited higher CCI scores and higher incidences of some CCI items. Moderate-to-severe liver disease, dementia, congestive heart failure, chronic pulmonary disease, and cerebrovascular disease all increase the risk of overall death in the Cox hazard model. The CCI-reinforced SVM and RF models are 85.18% and 81.76% accurate, respectively, whereas the SVM and RF models without the use of the CCI are relatively less accurate, at 75.81% and 74.83%, respectively. Therefore, CCI and some of its items are useful predictors of overall and prostate-cancer-specific survival and could constitute valuable features for machine-learning modeling.

show abstract

Androgen Deprivation Therapy Use Increases the Risk of Heart Failure in Patients With Prostate Cancer: A Population‐Based Cohort Study

Cited by 12 publications

References 34 publications

Resveratrol in Cancer Patients: From Bench to Bedside

Resveratrol in Cancer Patients: From Bench to Bedside

Cardiovascular Complications in Patients with Prostate Cancer: Potential Molecular Connections

Prediction of recurrence-associated death from localized prostate cancer with a charlson comorbidity index–reinforced machine learning model

Contact Info

Product

Resources

About